Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Conditions:   Advanced Solid Tumor;   Metastatic Cancer;   HER2-positive Breast Cancer;   HER2-positive Gastric Cancer;   HER-2 Protein Overexpression;   Esophageal Cancer;   Ovarian Cancer;   Endometrium Cancer;   Bladder Cancer;   Pancreatic Cancer;   Colorectal Cancer;   Non Smal l Cell Lung Cancer;   EGF-R Positive Non-Small Cell Lung Cancer;   Head and Neck Squamous Cell Carcinoma;   Triple Negative Breast Cancer;   Cervical Cancer;   Sarcoma Interventions:   Biological: SNK01;   Drug: Trastuzumab;   Drug: Cetuximab Sponsor:   NKMax America, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials